SAREPTA THERAPEUTICS INC (SRPT)

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,162 full-time employees. The firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company develops therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The company commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Company Info

SAREPTA THERAPEUTICS INC

215 1st St Ste 415

Cambridge MASSACHUSETTS 02142

P: 16172744000

CEO: Douglas S. Ingram

Employees: 1162

Website: https://www.sarepta.com/